Bifidobacterium animalis subsp. lactis 420 mitigates the pathological impact of myocardial infarction in the mouse

C. A. Danilo, E. Constantopoulos, L. A. McKee, H. Chen, J. A. Regan, Y. Lipovka, S. Lahtinen, L. K. Stenman, T. V.V. Nguyen, K. P. Doyle, M. J. Slepian, Z. I. Khalpey, J. P. Konhilas

Research output: Research - peer-reviewArticle

Abstract

There is a growing appreciation that our microbial environment in the gut plays a critical role in the maintenance of health and the pathogenesis of disease. Probiotic, beneficial gut microbes, administration can directly attenuate cardiac injury and post-myocardial infarction (MI) remodelling, yet the mechanisms of cardioprotection are unknown. We hypothesised that administration of Bifidobacterium animalis subsp. lactis 420 (B420), a probiotic with known anti-inflammatory properties, to mice will mitigate the pathological impact of MI, and that anti-inflammatory T regulatory (Treg) immune cells are necessary to impart protection against MI as a result of B420 administration. Wild-type male mice were administered B420, saline or Lactobacillus salivarius 33 (Ls-33) by gavage daily for 14 or 35 days, and underwent ischemia/reperfusion (I/R). Pretreatment with B420 for 10 or 28 days attenuated cardiac injury from I/R and reduced levels of inflammatory markers. Depletion of Treg cells by administration of anti-CD25 monoclonal antibodies eliminated B420-mediated cardio-protection. Further cytokine analysis revealed a shift from a pro-inflammatory to an anti-inflammatory environment in the probiotic treated post-MI hearts compared to controls. To summarise, B420 administration mitigates the pathological impact of MI. Next, we show that Treg immune cells are necessary to mediate B420-mediated protection against MI. Finally, we identify putative cellular, epigenetic and/or post-translational mechanisms of B420-mediated protection against MI.

LanguageEnglish (US)
Pages257-269
Number of pages13
JournalBeneficial Microbes
Volume8
Issue number2
DOIs
StatePublished - 2017

Fingerprint

Myocardial Infarction
Bifidobacterium animalis
Probiotics
Anti-Inflammatory Agents
Reperfusion Injury
Epigenomics
Reperfusion
Ischemia
Monoclonal Antibodies
Cytokines
Health
Wounds and Injuries
Lactobacillus salivarius
Thomsen-Friedenreich antibodies

Keywords

  • B. animalis ssp. lactis
  • Cardiovascular disease
  • Inflammation
  • Probiotics
  • Regulatory T cells

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)

Cite this

Danilo, C. A., Constantopoulos, E., McKee, L. A., Chen, H., Regan, J. A., Lipovka, Y., ... Konhilas, J. P. (2017). Bifidobacterium animalis subsp. lactis 420 mitigates the pathological impact of myocardial infarction in the mouse. Beneficial Microbes, 8(2), 257-269. DOI: 10.3920/BM2016.0119

Bifidobacterium animalis subsp. lactis 420 mitigates the pathological impact of myocardial infarction in the mouse. / Danilo, C. A.; Constantopoulos, E.; McKee, L. A.; Chen, H.; Regan, J. A.; Lipovka, Y.; Lahtinen, S.; Stenman, L. K.; Nguyen, T. V.V.; Doyle, K. P.; Slepian, M. J.; Khalpey, Z. I.; Konhilas, J. P.

In: Beneficial Microbes, Vol. 8, No. 2, 2017, p. 257-269.

Research output: Research - peer-reviewArticle

Danilo, CA, Constantopoulos, E, McKee, LA, Chen, H, Regan, JA, Lipovka, Y, Lahtinen, S, Stenman, LK, Nguyen, TVV, Doyle, KP, Slepian, MJ, Khalpey, ZI & Konhilas, JP 2017, 'Bifidobacterium animalis subsp. lactis 420 mitigates the pathological impact of myocardial infarction in the mouse' Beneficial Microbes, vol 8, no. 2, pp. 257-269. DOI: 10.3920/BM2016.0119
Danilo CA, Constantopoulos E, McKee LA, Chen H, Regan JA, Lipovka Y et al. Bifidobacterium animalis subsp. lactis 420 mitigates the pathological impact of myocardial infarction in the mouse. Beneficial Microbes. 2017;8(2):257-269. Available from, DOI: 10.3920/BM2016.0119
Danilo, C. A. ; Constantopoulos, E. ; McKee, L. A. ; Chen, H. ; Regan, J. A. ; Lipovka, Y. ; Lahtinen, S. ; Stenman, L. K. ; Nguyen, T. V.V. ; Doyle, K. P. ; Slepian, M. J. ; Khalpey, Z. I. ; Konhilas, J. P./ Bifidobacterium animalis subsp. lactis 420 mitigates the pathological impact of myocardial infarction in the mouse. In: Beneficial Microbes. 2017 ; Vol. 8, No. 2. pp. 257-269
@article{e8ec64ee27ff4c49848d85fcaed835ca,
title = "Bifidobacterium animalis subsp. lactis 420 mitigates the pathological impact of myocardial infarction in the mouse",
abstract = "There is a growing appreciation that our microbial environment in the gut plays a critical role in the maintenance of health and the pathogenesis of disease. Probiotic, beneficial gut microbes, administration can directly attenuate cardiac injury and post-myocardial infarction (MI) remodelling, yet the mechanisms of cardioprotection are unknown. We hypothesised that administration of Bifidobacterium animalis subsp. lactis 420 (B420), a probiotic with known anti-inflammatory properties, to mice will mitigate the pathological impact of MI, and that anti-inflammatory T regulatory (Treg) immune cells are necessary to impart protection against MI as a result of B420 administration. Wild-type male mice were administered B420, saline or Lactobacillus salivarius 33 (Ls-33) by gavage daily for 14 or 35 days, and underwent ischemia/reperfusion (I/R). Pretreatment with B420 for 10 or 28 days attenuated cardiac injury from I/R and reduced levels of inflammatory markers. Depletion of Treg cells by administration of anti-CD25 monoclonal antibodies eliminated B420-mediated cardio-protection. Further cytokine analysis revealed a shift from a pro-inflammatory to an anti-inflammatory environment in the probiotic treated post-MI hearts compared to controls. To summarise, B420 administration mitigates the pathological impact of MI. Next, we show that Treg immune cells are necessary to mediate B420-mediated protection against MI. Finally, we identify putative cellular, epigenetic and/or post-translational mechanisms of B420-mediated protection against MI.",
keywords = "B. animalis ssp. lactis, Cardiovascular disease, Inflammation, Probiotics, Regulatory T cells",
author = "Danilo, {C. A.} and E. Constantopoulos and McKee, {L. A.} and H. Chen and Regan, {J. A.} and Y. Lipovka and S. Lahtinen and Stenman, {L. K.} and Nguyen, {T. V.V.} and Doyle, {K. P.} and Slepian, {M. J.} and Khalpey, {Z. I.} and Konhilas, {J. P.}",
year = "2017",
doi = "10.3920/BM2016.0119",
volume = "8",
pages = "257--269",
journal = "Beneficial microbes",
issn = "1876-2883",
publisher = "Wageningen Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Bifidobacterium animalis subsp. lactis 420 mitigates the pathological impact of myocardial infarction in the mouse

AU - Danilo,C. A.

AU - Constantopoulos,E.

AU - McKee,L. A.

AU - Chen,H.

AU - Regan,J. A.

AU - Lipovka,Y.

AU - Lahtinen,S.

AU - Stenman,L. K.

AU - Nguyen,T. V.V.

AU - Doyle,K. P.

AU - Slepian,M. J.

AU - Khalpey,Z. I.

AU - Konhilas,J. P.

PY - 2017

Y1 - 2017

N2 - There is a growing appreciation that our microbial environment in the gut plays a critical role in the maintenance of health and the pathogenesis of disease. Probiotic, beneficial gut microbes, administration can directly attenuate cardiac injury and post-myocardial infarction (MI) remodelling, yet the mechanisms of cardioprotection are unknown. We hypothesised that administration of Bifidobacterium animalis subsp. lactis 420 (B420), a probiotic with known anti-inflammatory properties, to mice will mitigate the pathological impact of MI, and that anti-inflammatory T regulatory (Treg) immune cells are necessary to impart protection against MI as a result of B420 administration. Wild-type male mice were administered B420, saline or Lactobacillus salivarius 33 (Ls-33) by gavage daily for 14 or 35 days, and underwent ischemia/reperfusion (I/R). Pretreatment with B420 for 10 or 28 days attenuated cardiac injury from I/R and reduced levels of inflammatory markers. Depletion of Treg cells by administration of anti-CD25 monoclonal antibodies eliminated B420-mediated cardio-protection. Further cytokine analysis revealed a shift from a pro-inflammatory to an anti-inflammatory environment in the probiotic treated post-MI hearts compared to controls. To summarise, B420 administration mitigates the pathological impact of MI. Next, we show that Treg immune cells are necessary to mediate B420-mediated protection against MI. Finally, we identify putative cellular, epigenetic and/or post-translational mechanisms of B420-mediated protection against MI.

AB - There is a growing appreciation that our microbial environment in the gut plays a critical role in the maintenance of health and the pathogenesis of disease. Probiotic, beneficial gut microbes, administration can directly attenuate cardiac injury and post-myocardial infarction (MI) remodelling, yet the mechanisms of cardioprotection are unknown. We hypothesised that administration of Bifidobacterium animalis subsp. lactis 420 (B420), a probiotic with known anti-inflammatory properties, to mice will mitigate the pathological impact of MI, and that anti-inflammatory T regulatory (Treg) immune cells are necessary to impart protection against MI as a result of B420 administration. Wild-type male mice were administered B420, saline or Lactobacillus salivarius 33 (Ls-33) by gavage daily for 14 or 35 days, and underwent ischemia/reperfusion (I/R). Pretreatment with B420 for 10 or 28 days attenuated cardiac injury from I/R and reduced levels of inflammatory markers. Depletion of Treg cells by administration of anti-CD25 monoclonal antibodies eliminated B420-mediated cardio-protection. Further cytokine analysis revealed a shift from a pro-inflammatory to an anti-inflammatory environment in the probiotic treated post-MI hearts compared to controls. To summarise, B420 administration mitigates the pathological impact of MI. Next, we show that Treg immune cells are necessary to mediate B420-mediated protection against MI. Finally, we identify putative cellular, epigenetic and/or post-translational mechanisms of B420-mediated protection against MI.

KW - B. animalis ssp. lactis

KW - Cardiovascular disease

KW - Inflammation

KW - Probiotics

KW - Regulatory T cells

UR - http://www.scopus.com/inward/record.url?scp=85018262974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018262974&partnerID=8YFLogxK

U2 - 10.3920/BM2016.0119

DO - 10.3920/BM2016.0119

M3 - Article

VL - 8

SP - 257

EP - 269

JO - Beneficial microbes

T2 - Beneficial microbes

JF - Beneficial microbes

SN - 1876-2883

IS - 2

ER -